Koji Oba1, Xavier Paoletti, Steven Alberts, Yung-Jue Bang, Jacqueline Benedetti, Harry Bleiberg, Paul Catalano, Florian Lordick, Stefan Michiels, Satoshi Morita, Yasuo Ohashi, Jean-Pierre Pignon, Philippe Rougier, Mitsuru Sasako, Junichi Sakamoto, Daniel Sargent, Kohei Shitara, Eric Van Cutsem, Marc Buyse, Tomasz Burzykowski. 1. Affiliations of authors: Translational Research and Clinical Trial Center, Hokkaido University Hospital, Sapporo, Japan (KO); Biostatistics dpt, INSEM U900, Institut Curie, Paris, France (XP); Mayo Clinic, Rochester, MN (SA, DS); Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea (Y-JB); SWOG Statistical Center, Seattle, WA (JB); Brussels, Belgium (HB); Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Department of Biostatistics, Harvard School of Public Health, Boston, MA (PC); University Clinic Leipzig, University Cancer Center, Leipzig, Germany (FL); Biostatistics and Epidemiology department, Institut Gustave-Roussy, Universite Paris XI, Villejuif, France (SMi, J-PP); Department of Biostatistics, Yokohama City University, Yokohama, Japan (SMo); Department of Biostatistics, School of Public Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan (YO); Gastro-enterology department, University Hospital Europeen Georges Pompidou, Paris, France (PR); Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan (MS); Tokai Central Hospital, Kakumuhara, Japan (JS); Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan (KS); Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium (EVC); International Drug Development Institute, Louvain-la-Neuve, Belgium (MB, TB); I-BioStat, Hasselt University, Diepenbeek, Belgium (MB, TB).
Abstract
BACKGROUND: In investigations of the effectiveness of surgery and adjuvant chemotherapy for gastric cancers, overall survival (OS) is considered the gold standard endpoint. However, the disadvantage of using OS as the endpoint is that it requires an extended follow-up period. We sought to investigate whether disease-free survival (DFS) is a valid surrogate for OS in trials of adjuvant chemotherapy for gastric cancer. METHODS: The GASTRIC group initiated a meta-analysis of individual patient data collected in randomized clinical trials comparing adjuvant chemotherapy vs surgery alone for patients with curatively resected gastric cancer. Surrogacy of DFS was assessed through the correlation between the endpoints as well as through the correlation between the treatment effects on the endpoints. External validation of the prediction based on DFS was also evaluated. RESULTS: Individual patient data from 14 randomized clinical trials that included a total of 3288 patients were analyzed. The rank correlation coefficient between DFS and OS was 0.974 (95% confidence interval [CI] = 0.971 to 0.976). The coefficient of determination between the treatment effects on DFS and on OS was as high as 0.964 (95% CI = 0.926 to 1.000), and the surrogate threshold effect based on adjusted regression analysis was 0.92. In external validation, the six hazard ratios for OS predicted according to DFS were in very good agreement with those actually observed for OS. CONCLUSIONS: DFS is an acceptable surrogate for OS in trials of cytotoxic agents for gastric cancer in the adjuvant setting.
BACKGROUND: In investigations of the effectiveness of surgery and adjuvant chemotherapy for gastric cancers, overall survival (OS) is considered the gold standard endpoint. However, the disadvantage of using OS as the endpoint is that it requires an extended follow-up period. We sought to investigate whether disease-free survival (DFS) is a valid surrogate for OS in trials of adjuvant chemotherapy for gastric cancer. METHODS: The GASTRIC group initiated a meta-analysis of individual patient data collected in randomized clinical trials comparing adjuvant chemotherapy vs surgery alone for patients with curatively resected gastric cancer. Surrogacy of DFS was assessed through the correlation between the endpoints as well as through the correlation between the treatment effects on the endpoints. External validation of the prediction based on DFS was also evaluated. RESULTS: Individual patient data from 14 randomized clinical trials that included a total of 3288 patients were analyzed. The rank correlation coefficient between DFS and OS was 0.974 (95% confidence interval [CI] = 0.971 to 0.976). The coefficient of determination between the treatment effects on DFS and on OS was as high as 0.964 (95% CI = 0.926 to 1.000), and the surrogate threshold effect based on adjusted regression analysis was 0.92. In external validation, the six hazard ratios for OS predicted according to DFS were in very good agreement with those actually observed for OS. CONCLUSIONS: DFS is an acceptable surrogate for OS in trials of cytotoxic agents for gastric cancer in the adjuvant setting.
Authors: E Bajetta; R Buzzoni; L Mariani; E Beretta; F Bozzetti; G Bordogna; E Aitini; S Fava; G Schieppati; G Pinotti; M Visini; G Ianniello; Bartolomeo M Di Journal: Ann Oncol Date: 2002-02 Impact factor: 32.976
Authors: J E Krook; M J O'Connell; H S Wieand; R W Beart; J E Leigh; J W Kugler; J F Foley; D M Pfeifle; D I Twito Journal: Cancer Date: 1991-05-15 Impact factor: 6.860
Authors: M Lise; D Nitti; A Marchet; T Sahmoud; M Buyse; N Duez; M Fiorentino; J G Dos Santos; R Labianca; P Rougier Journal: J Clin Oncol Date: 1995-11 Impact factor: 44.544
Authors: Koji Oba; Xavier Paoletti; Yung-Jue Bang; Harry Bleiberg; Tomasz Burzykowski; Nozomu Fuse; Stefan Michiels; Satoshi Morita; Yasuo Ohashi; Jean-Pierre Pignon; Philippe Rougier; Junichi Sakamoto; Daniel Sargent; Mitsuru Sasako; Kohei Shitara; Akira Tsuburaya; Eric Van Cutsem; Marc Buyse Journal: Eur J Cancer Date: 2013-01-24 Impact factor: 9.162
Authors: T Nakajima; T Kinoshita; A Nashimoto; M Sairenji; T Yamaguchi; J Sakamoto; T Fujiya; T Inada; M Sasako; Y Ohashi Journal: Br J Surg Date: 2007-12 Impact factor: 6.939
Authors: F De Vita; F Giuliani; M Orditura; E Maiello; G Galizia; N Di Martino; F Montemurro; G Cartenì; L Manzione; S Romito; V Gebbia; F Ciardiello; G Catalano; G Colucci Journal: Ann Oncol Date: 2007-05-24 Impact factor: 32.976
Authors: Ryan F Herde; Kristine E Kokeny; Chakravarthy B Reddy; Wallace L Akerley; Nan Hu; Jonathan P Boltax; Ying J Hitchcock Journal: Am J Clin Oncol Date: 2018-01 Impact factor: 2.339
Authors: Federico Rotolo; Jean-Pierre Pignon; Jean Bourhis; Sophie Marguet; Julie Leclercq; Wai Tong Ng; Jun Ma; Anthony T C Chan; Pei-Yu Huang; Guopei Zhu; Daniel T T Chua; Yong Chen; Hai-Qiang Mai; Dora L W Kwong; Yoke Lim Soong; James Moon; Yuk Tung; Kwan-Hwa Chi; George Fountzilas; Li Zhang; Edwin Pun Hui; Anne W M Lee; Pierre Blanchard; Stefan Michiels Journal: J Natl Cancer Inst Date: 2017-04 Impact factor: 13.506
Authors: Maria Di Bartolomeo; Filippo Pietrantonio; Alessandro Pellegrinelli; Antonia Martinetti; Luigi Mariani; Maria Grazia Daidone; Emilio Bajetta; Giuseppe Pelosi; Filippo de Braud; Irene Floriani; Rosalba Miceli Journal: Gastric Cancer Date: 2015-04-11 Impact factor: 7.370